Trends in net survival from liver cancer in six European Latin countries: Results from the SUDCAN population-based study

S. Ferretti, N. Bossard, F. Binder-Fouchard, J. Faivre, A. Bordoni, P. Biavati, A. Frassoldati, Diego Serraino, Antonella Zucchetto

Research output: Contribution to journalArticle

Abstract

Liver cancer represents a major clinical challenge. The aim of the SUDCAN collaborative study was to compare the net survival from liver cancer between six European Latin countries (Belgium, France, Italy, Portugal, Spain and Switzerland) and provide trends in net survival and dynamics of excess mortality rates (EMRs) up to 5 years after diagnosis. The data were extracted from the EUROCARE-5 database. First, net survival was studied over the period 2000-2004 using the Pohar-Perme estimator. For trend analyses, the study period was specific to each country. Results are reported from 1992 to 2004 in France, Italy, Spain and Switzerland and from 2000 to 2004 in Belgium and Portugal. These trend analyses were carried out using a flexible excess-rate modeling strategy. There were little differences between the six countries in the 5-year age-standardized net survival (2000-2004): it ranged from 13% (France and Portugal) to 16% (Belgium). An increase in the net age-standardized survival was observed in all countries between 1992 and 2004, both at 1 year and at 5 years (the highest in Spain, the lowest in France). Generally, patients aged 60 years showed the highest increase. There was a progressive decrease in EMR over the 5-year-period following diagnosis. The study confirmed the poor prognosis of liver cancer. Innovative treatments might improve the prognosis as well as preventive screening of cirrhotic patients with good liver function. Efforts are also needed to improve registration practices. Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.
Original languageEnglish
Pages (from-to)S56-S62
Number of pages7
JournalEuropean Journal of Cancer Prevention
Volume26
Issue numbersupp 1
DOIs
Publication statusPublished - 2017

Fingerprint

Liver Neoplasms
France
Portugal
Belgium
Survival
Spain
Mortality
Population
Switzerland
Italy
Demography
Databases
Liver
Health
Therapeutics

Keywords

  • Cancer registries
  • Europe
  • Excess mortality rate
  • Liver cancer
  • Net survival
  • Trends in survival
  • adult
  • aged
  • Article
  • Belgium
  • cancer mortality
  • cancer patient
  • cancer prognosis
  • cancer registry
  • cancer screening
  • cancer survival
  • comparative study
  • experimental therapy
  • female
  • France
  • human
  • ICD-O-3
  • Italy
  • liver cancer
  • liver function test
  • major clinical study
  • male
  • medical record
  • mortality rate
  • Portugal
  • priority journal
  • Spain
  • Switzerland

Cite this

Trends in net survival from liver cancer in six European Latin countries: Results from the SUDCAN population-based study. / Ferretti, S.; Bossard, N.; Binder-Fouchard, F.; Faivre, J.; Bordoni, A.; Biavati, P.; Frassoldati, A.; Serraino, Diego; Zucchetto, Antonella.

In: European Journal of Cancer Prevention, Vol. 26, No. supp 1, 2017, p. S56-S62.

Research output: Contribution to journalArticle

Ferretti, S. ; Bossard, N. ; Binder-Fouchard, F. ; Faivre, J. ; Bordoni, A. ; Biavati, P. ; Frassoldati, A. ; Serraino, Diego ; Zucchetto, Antonella. / Trends in net survival from liver cancer in six European Latin countries: Results from the SUDCAN population-based study. In: European Journal of Cancer Prevention. 2017 ; Vol. 26, No. supp 1. pp. S56-S62.
@article{9b316d92e3674e6cb2320cc9e5db1984,
title = "Trends in net survival from liver cancer in six European Latin countries: Results from the SUDCAN population-based study",
abstract = "Liver cancer represents a major clinical challenge. The aim of the SUDCAN collaborative study was to compare the net survival from liver cancer between six European Latin countries (Belgium, France, Italy, Portugal, Spain and Switzerland) and provide trends in net survival and dynamics of excess mortality rates (EMRs) up to 5 years after diagnosis. The data were extracted from the EUROCARE-5 database. First, net survival was studied over the period 2000-2004 using the Pohar-Perme estimator. For trend analyses, the study period was specific to each country. Results are reported from 1992 to 2004 in France, Italy, Spain and Switzerland and from 2000 to 2004 in Belgium and Portugal. These trend analyses were carried out using a flexible excess-rate modeling strategy. There were little differences between the six countries in the 5-year age-standardized net survival (2000-2004): it ranged from 13{\%} (France and Portugal) to 16{\%} (Belgium). An increase in the net age-standardized survival was observed in all countries between 1992 and 2004, both at 1 year and at 5 years (the highest in Spain, the lowest in France). Generally, patients aged 60 years showed the highest increase. There was a progressive decrease in EMR over the 5-year-period following diagnosis. The study confirmed the poor prognosis of liver cancer. Innovative treatments might improve the prognosis as well as preventive screening of cirrhotic patients with good liver function. Efforts are also needed to improve registration practices. Copyright {\circledC} 2017 Wolters Kluwer Health, Inc. All rights reserved.",
keywords = "Cancer registries, Europe, Excess mortality rate, Liver cancer, Net survival, Trends in survival, adult, aged, Article, Belgium, cancer mortality, cancer patient, cancer prognosis, cancer registry, cancer screening, cancer survival, comparative study, experimental therapy, female, France, human, ICD-O-3, Italy, liver cancer, liver function test, major clinical study, male, medical record, mortality rate, Portugal, priority journal, Spain, Switzerland",
author = "S. Ferretti and N. Bossard and F. Binder-Fouchard and J. Faivre and A. Bordoni and P. Biavati and A. Frassoldati and Diego Serraino and Antonella Zucchetto",
note = "Export Date: 20 February 2018 CODEN: EJUPE Correspondence Address: Ferretti, S.; Ferrara Local Health Unit, Area Vasta Emilia Centrale Cancer Registry, University of FerraraItaly; email: frs@unife.it",
year = "2017",
doi = "10.1097/CEJ.0000000000000298",
language = "English",
volume = "26",
pages = "S56--S62",
journal = "European Journal of Cancer Prevention",
issn = "0959-8278",
publisher = "Lippincott Williams and Wilkins",
number = "supp 1",

}

TY - JOUR

T1 - Trends in net survival from liver cancer in six European Latin countries: Results from the SUDCAN population-based study

AU - Ferretti, S.

AU - Bossard, N.

AU - Binder-Fouchard, F.

AU - Faivre, J.

AU - Bordoni, A.

AU - Biavati, P.

AU - Frassoldati, A.

AU - Serraino, Diego

AU - Zucchetto, Antonella

N1 - Export Date: 20 February 2018 CODEN: EJUPE Correspondence Address: Ferretti, S.; Ferrara Local Health Unit, Area Vasta Emilia Centrale Cancer Registry, University of FerraraItaly; email: frs@unife.it

PY - 2017

Y1 - 2017

N2 - Liver cancer represents a major clinical challenge. The aim of the SUDCAN collaborative study was to compare the net survival from liver cancer between six European Latin countries (Belgium, France, Italy, Portugal, Spain and Switzerland) and provide trends in net survival and dynamics of excess mortality rates (EMRs) up to 5 years after diagnosis. The data were extracted from the EUROCARE-5 database. First, net survival was studied over the period 2000-2004 using the Pohar-Perme estimator. For trend analyses, the study period was specific to each country. Results are reported from 1992 to 2004 in France, Italy, Spain and Switzerland and from 2000 to 2004 in Belgium and Portugal. These trend analyses were carried out using a flexible excess-rate modeling strategy. There were little differences between the six countries in the 5-year age-standardized net survival (2000-2004): it ranged from 13% (France and Portugal) to 16% (Belgium). An increase in the net age-standardized survival was observed in all countries between 1992 and 2004, both at 1 year and at 5 years (the highest in Spain, the lowest in France). Generally, patients aged 60 years showed the highest increase. There was a progressive decrease in EMR over the 5-year-period following diagnosis. The study confirmed the poor prognosis of liver cancer. Innovative treatments might improve the prognosis as well as preventive screening of cirrhotic patients with good liver function. Efforts are also needed to improve registration practices. Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.

AB - Liver cancer represents a major clinical challenge. The aim of the SUDCAN collaborative study was to compare the net survival from liver cancer between six European Latin countries (Belgium, France, Italy, Portugal, Spain and Switzerland) and provide trends in net survival and dynamics of excess mortality rates (EMRs) up to 5 years after diagnosis. The data were extracted from the EUROCARE-5 database. First, net survival was studied over the period 2000-2004 using the Pohar-Perme estimator. For trend analyses, the study period was specific to each country. Results are reported from 1992 to 2004 in France, Italy, Spain and Switzerland and from 2000 to 2004 in Belgium and Portugal. These trend analyses were carried out using a flexible excess-rate modeling strategy. There were little differences between the six countries in the 5-year age-standardized net survival (2000-2004): it ranged from 13% (France and Portugal) to 16% (Belgium). An increase in the net age-standardized survival was observed in all countries between 1992 and 2004, both at 1 year and at 5 years (the highest in Spain, the lowest in France). Generally, patients aged 60 years showed the highest increase. There was a progressive decrease in EMR over the 5-year-period following diagnosis. The study confirmed the poor prognosis of liver cancer. Innovative treatments might improve the prognosis as well as preventive screening of cirrhotic patients with good liver function. Efforts are also needed to improve registration practices. Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.

KW - Cancer registries

KW - Europe

KW - Excess mortality rate

KW - Liver cancer

KW - Net survival

KW - Trends in survival

KW - adult

KW - aged

KW - Article

KW - Belgium

KW - cancer mortality

KW - cancer patient

KW - cancer prognosis

KW - cancer registry

KW - cancer screening

KW - cancer survival

KW - comparative study

KW - experimental therapy

KW - female

KW - France

KW - human

KW - ICD-O-3

KW - Italy

KW - liver cancer

KW - liver function test

KW - major clinical study

KW - male

KW - medical record

KW - mortality rate

KW - Portugal

KW - priority journal

KW - Spain

KW - Switzerland

U2 - 10.1097/CEJ.0000000000000298

DO - 10.1097/CEJ.0000000000000298

M3 - Article

VL - 26

SP - S56-S62

JO - European Journal of Cancer Prevention

JF - European Journal of Cancer Prevention

SN - 0959-8278

IS - supp 1

ER -